泪腺腺样囊性癌的分期及临床治疗进展
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

天津市临床重点学科(专科)建设项目(No.TJLCZDXKQ020)


Development of stage and clinical treatment for adenoid cystic carcinoma of lacrimal gland
Author:
Affiliation:

Fund Project:

Tianjin Key Clinical Discipline Construction Project(No.TJLCZDXKQ020)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    泪腺腺样囊性癌是泪腺最常见的恶性上皮性肿瘤,手术治疗效果不理想。近年来,随着多种放射治疗和化学治疗的应用,泪腺腺样囊性癌的治疗模式发生较大转变。一方面,临床分期逐步完善,以新的分期为基础的综合治疗得到规范化应用; 另一方面,在质子放疗、中子放疗、经动脉细胞减容化疗等新辅助治疗的支持下,保眼手术逐渐增多,局部复发率和转移率逐渐降低,无病生存期获得延长,但还需要长期观察。本文就近年来国际上泪腺腺样囊性癌相关方面的治疗进展进行综述,以提供新的参考依据。

    Abstract:

    Adenoid cystic carcinoma of lacrimal gland is the most common malignant epithelial tumor of the lacrimal gland, and surgical treatment alone shows unsatisfactory result. In recent years, as the application of radiotherapy and chemotherapy, changes have happened in the treatment modality for adenoid cystic carcinoma of lacrimal gland. On one hand, clinical staging is gradually refined, which promote the application of standardized comprehensive treatment. On the other hand, neoadjuvant therapies, such as proton radiotherapy, neutron radiotherapy and intra-arterial cytoreductive chemotherapy, can further improve the application of eye-sparing surgery, decrease the rate of local recurrence and metastasis, and prolong the disease-free survival. In this review, we attempt to arrive at some general insights regarding the progress of treatment in adenoid cystic carcinoma of lacrimal gland, in order to provide new reference basis.

    参考文献
    相似文献
    引证文献
引用本文

简天明,孙丰源.泪腺腺样囊性癌的分期及临床治疗进展.国际眼科杂志, 2020,20(7):1187-1191.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2019-10-17
  • 最后修改日期:2020-05-29
  • 录用日期:
  • 在线发布日期: 2020-06-22
  • 出版日期:
文章二维码